AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial

AZN•2026-08-27

Tezspire meets main and secondary goals in late-stage trial

AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.

AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial

Tezspire meets main and secondary goals in late-stage trial

Related News

Braze Inc <BRZE.O>: TD Cowen Raises Target Price to $36 From $30

Asia's crude oil imports stay soft in August, challenging US Hormuz claims: Russell

Nvidia Corporation <NVDA.O>: Morgan Stanley Raises Target Price to $300 from $288

Himalaya Shipping converts two vessels to fixed-rate charters at about US$ 53,000 a day

Kemper Corporation <KMPR.N>: TD Cowen Cuts Target Price to $42 From $81